Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients

Mometasone Furoate Cream Reduces Acute Radiation Dermatitis in Head and Neck Squamous Cell Carcinomas' Patients Receiving Radiation Therapy

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02495064

Enrollment

160

Registered

2015-07-13

Start date

2015-01-31

Completion date

2016-12-31

Last updated

2016-03-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Radiation Dermatitis

Brief summary

Radiation dermatitis is an acute effect of radiation therapy,Especially in the neck skin of head and neck squamous cell carcinomas' patients.The investigators wanted to confirm the benefit of mometasone furoate (MF) in preventing acute radiation reactions, as shown in a previous study.

Detailed description

A randomized,self-comparative controlled trial was undertaken comparing MF cream with no cream administered from the first day of treatment for 5-6 weeks to prevent radiation dermatitis of neck during radiation therapy to the head and neck squamous cell carcinomas' Patients. One side of patients' neck will begin to use MF cream from the first day of radiation therapy, while the other side accept no preventive measures.

Interventions

DRUGMometasone Furoate Cream

One side of patients' neck will begain to use MF cream from the first day of radiation therapy.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

12 Years to No maximum

Healthy volunteers

Inclusion criteria

* pathological diagnosis for head and neck squamous cell carcinomas and * going to have radiotherapy.

Exclusion criteria

* pregnant, * lactating women, * infants, * elderly people with atrophy skin, * allergic constitution patients, * the corresponding parts of 5 radiotherapy skin ulceration or infection and * allergic patients to Mometasone Furoate Cream.

Design outcomes

Primary

Measure	Time frame	Description
the mean Radiation Therapy Oncology Group (RTOG) skin dermatitis score	seven weeks	The investigators descriph the skin dermatitis scores every week during radiation therapy and the later two weeks as follows:The scores were 0 = no visible change; 1 = faint or dull erythema; 2 = tender or bright erythema with or without moist desquamation; 3 = patchy moist desquamation with moderate edema; and 4= confluent moist desquamation with pitting edema.

Countries

China

Contacts

Primary ContactLiao Yao

425838503@qq.com0086-13778106466

Backup ContactDu X Bo

duxiaobo2005@126.com0086-13550822229

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026